REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity
Back to Research Library

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

A recent study launched by Eli Lilly and Company aims to explore how fasting duration and withholding of tirzepatide—a popular peptide therapy—impact stomach contents after a meal. The findings could offer valuable insights into the effectiveness and mechanisms of this treatment, particularly for individuals with type 2 diabetes mellitus (T2DM) or those struggling with obesity without T2DM.

Background

Peptide therapies have gained significant traction in recent years due to their potential benefits in managing chronic conditions like diabetes and obesity. Tirzepatide, one such therapy, has shown promise in clinical trials for its ability to control blood sugar levels and promote weight loss. However, understanding how various factors, including fasting times and drug discontinuation, affect the body's response is crucial.

This study, which can be found on ClinicalTrials.gov (NCT07299084), marks an important step in unraveling these dynamics. By using ultrasound technology to measure stomach contents post-meal, researchers aim to provide a clearer picture of how tirzepatide interacts with the digestive system under different conditions.

Key Details

The study is currently active but not recruiting participants, indicating that it has moved past its initial phases and is likely collecting data. Sponsored by Eli Lilly and Company, this Phase 1 clinical trial focuses on evaluating the effect of fasting duration and tirzepatide withholding on stomach content volume in two distinct groups: individuals with T2DM and those without diabetes but who are overweight or obese.

Participants will undergo a test meal scenario where ultrasound scans will be used to measure the amount of food and fluid remaining in their stomachs. The study is designed to shed light on how different fasting periods and pauses in taking tirzepatide influence gastric emptying rates, which could have significant implications for treatment regimens and patient care.

Key Takeaways

  • Understanding Gastric Emptying: This research provides a deeper understanding of how fasting and drug discontinuation affect the rate at which food leaves the stomach.
  • Clinical Utility of Tirzepatide: By examining tirzepatide's effects in both diabetic and non-diabetic obese populations, this study offers critical insights into its broader clinical utility.
  • Regulatory Implications: Data from this trial could influence FDA regulations regarding medication administration guidelines for patients using peptide therapies like tirzepatide.
  • Patient Care Strategies: Insights gained may lead to more personalized treatment plans that account for fasting and drug adherence factors, enhancing patient outcomes.

What This Means

For the peptide community, including researchers, clinicians, and informed consumers, this study underscores the importance of continuous research into how these innovative treatments work in real-world scenarios. Understanding the nuances of gastric emptying under varying conditions can lead to more effective therapeutic strategies and better management of chronic diseases such as diabetes and obesity.

Moreover, the findings could pave the way for future studies that delve even deeper into the mechanisms behind peptide therapies, ultimately contributing to advancements in personalized medicine and improved patient care across various health disciplines.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07299084) — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.